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Abstract
Background Researchers increasingly use intraoperative muscle biopsy to investigate mechanisms of skeletal muscle atrophy
in patients with cancer. Muscles have been assessed for morphological, cellular, and biochemical features. The aim of this
study was to conduct a state-of-the-science review of this literature and, secondly, to evaluate clinical and biological variation
in biopsies of rectus abdominis (RA) muscle from a cohort of patients with malignancies.
Methods Literature was searched for reports on muscle biopsies from patients with a cancer diagnosis. Quality of reports
and risk of bias were assessed. Data abstracted included patient characteristics and diagnoses, sample size, tissue collection
and biobanking procedures, and results. A cohort of cancer patients (n = 190, 88% gastrointestinal malignancies), who
underwent open abdominal surgery as part of their clinical care, consented to RA biopsy from the site of incision. Computed
tomography (CT) scans were used to quantify total abdominal muscle and RA cross-sectional areas and radiodensity. Biopsies
were assessed for muscle fibre area (μm2), fibre types, myosin heavy chain isoforms, and expression of genes selected for their
involvement in catabolic pathways of muscle.
Results Muscle biopsy occurred in 59 studies (total N = 1585 participants). RA was biopsied intraoperatively in 40 studies
(67%), followed by quadriceps (26%; percutaneous biopsy) and other muscles (7%). Cancer site and stage, % of male partici-
pants, and age were highly variable between studies. Details regarding patient medical history and biopsy procedures were
frequently absent. Lack of description of the population(s) sampled and low sample size contributed to low quality and risk
of bias. Weight-losing cases were compared with weight stable cancer or healthy controls without considering a measure of
muscle mass in 21 out of 44 studies. In the cohort of patients providing biopsy for this study, 78% of patients had preoperative
CT scans and a high proportion (64%) met published criteria for sarcopenia. Fibre type distribution in RA was type I (46% ± 13),
hybrid type I/IIA (1% ± 1), type IIA (36% ± 10), hybrid type IIA/D (15% ± 14), and type IID (2% ± 5). Sexual dimorphism was
prominent in RA CT cross-sectional area, mean fibre cross-sectional area, and in expression of genes associated with muscle
growth, apoptosis, and inflammation (P < 0.05). Medical history revealed multiple co-morbid conditions and medications.
Conclusions Continued collaboration between researchers and cancer surgeons enables a more complete understanding of
mechanisms of cancer-associated muscle atrophy. Standardization of biobanking practices, tissue manipulation, patient char-
acterization, and classification will enhance the consistency, reliability, and comparability of future studies.
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Introduction
Several radiologically defined features of skeletal muscle have
been associated with clinical outcomes in patients with
cancer. Reduced muscle mass (i.e. sarcopenia), loss of muscle
mass over time, and reduced muscle radiodensity are related
to mortality, shorter progression—free survival, chemother-
apy toxicity, and complications of cancer surger.1–4 In light
of the associations between muscle and outcomes,
researchers are increasingly investigating the pathophysiol-
ogy of muscle abnormalities5–7 and attempting to relate the
findings to the much broader base of knowledge that exists
from research in animal models. Muscle may be obtained
from cancer patients by percutaneous biopsy as well as
intraoperatively during cancer surgery. Clinical data aligned
with the biopsy provides a comprehensive approach to
understand cancer cachexia from the vantage point of muscle
wasting. Evaluation of human muscle contributes significantly
to the understanding of molecular mechanisms in a variety of
primary pathologies of skeletal muscle.8,9
Biopsy and tissue manipulation techniques can induce
changes in the muscle that alter enzyme activity,
metabolite concentrations, and protein metabolism.10–12
Also, patient characteristics such as age, sex, cancer type,
co-morbidities, and medications (including chemotherapy)
taken at the time of biopsy collection are known factors
that influence muscle metabolism.13–17 These methodologi-
cal issues pose limitations in the reliability, interpretation,
and comparability of the findings on muscle biopsies in
patients with cancer. Therefore, our first aim was to
conduct a state-of-the-science review of the literature on
muscle biopsy in cancer patients. This type of review
retains many features of a systematic review except that
studies are not excluded on the basis of a quality
assessment and thus presents a broader search of
the literature. An associated aim was to provide
recommendations of components to consider when evalu-
ating and reporting results of muscle biopsies from cancer
patients.
The second aim of this study was to evaluate sources of
variation in the muscle biopsy material to better understand
the risk of sampling bias, to determine variance and effect
size to enable sample size calculations, and to determine
the possible consequences of sexual dimorphism and age as
confounders using a relatively well-powered sample (n =
190). Our research group has experience in the radiological
characterization of muscle2,18,19 and skeletal muscle morphol-
ogy, cell biology, and biochemistry.7,20–22 Our collaborative
effort with hepatopancreatobiliary cancer surgeons has en-
abled muscle biobanking and exploration of muscle biology
within large populations. We have published studies on mus-
cle expression of mRNA, microRNA, and alternative splice var-
iants,20,21,23 alongside specific and precise measures of
muscle mass, radiodensity, and muscle loss.
Materials and methods
Literature review
A state-of-the-science review24 is a broad search of the liter-
ature that includes all studies in a particular area. Our review
protocol follows the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses25 guidelines to reduce bias
(Figure 1). Articles indexed in SCOPUS from 1 January 1900
to 16 August 2018 were queried to capture reports on
skeletal muscle biopsies from cancer patients. Search terms
included adult humans, malignant disease [(cancer) OR
(neoplasm) OR (carcinoma) OR (tumor) OR (malignant) OR
(metastasis)], skeletal muscle [(skeletal muscle) OR (muscle
mass) OR (lean body mass) OR (rectus abdominis) OR
(cachexia) OR terms for other specific muscle], and biopsy.
Review articles and studies on experimental models, labora-
tory animals, non-cancer populations, or those not employing
muscle biopsies were excluded. Bibliographies of identified
articles were hand searched to find additional relevant publi-
cations. There were no exclusion criteria regarding number of
patients and type of study (retrospective, prospective, or
cross sectional). Data were extracted from the result sections,
tables, and figures of each article. As we did not aggregate
the data, no additional data were contributed from the
investigators.
Two reviewers independently assessed each of the
included studies, and disagreements were resolved by con-
sensus. A score for study quality was given using assessment
tools provided by the National Heart, Lung and Blood Insti-
tute (NIH—U.S. Department of Health & Human Services)
for cross-sectional, cohort, case-control, randomized control
trials and before–after studies. The Newcastle–Ottawa scale
modified for cross-sectional studies26 was used to give a bias
score based on the (i) representativeness, (ii) size, and (iii)
non-respondent report.
Rectus abdominis biological characterization
Subjects and acquisition of muscle samples
The study was approved by the Health Research Ethics Board
of Alberta-Cancer. Patients undergoing elective abdominal
surgery were consecutively approached to participate in
tumour and tissue banking at a hepatopancreatobiliary surgi-
cal service in Alberta, Canada. Three per cent of approached
patients declined participation. Patients provided written in-
formed consent for muscle biopsy and tissue banking.
Release of n = 190 samples from the bank for analysis, as well
as patient information (demographic, clinical, and operative
data) from medical records, was performed under the aus-
pices of Protocol ETH-21709: The Molecular Profile of Cancer
Cachexia. Patients consent freely to muscle biopsy from the
site of incision at the time of surgery, as this entails little if
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any incremental discomfort or risk, as the surgery is inher-
ently invasive. All patients were either diagnosed as having
cancer or were suspected of having cancer due to their
symptoms and radiological assessments such as computed
tomography (CT) imaging.
The study cohort and conditions for acquisition of muscle
samples have been described previously.23 Briefly, rectus
abdominis (0.5–3 g) samples were collected during open
abdominal surgery scheduled as part of their clinical care.
Upper abdominal transverse incision was performed, and
muscle biopsy was obtained at opening by sharp dissection,
without the use of electrocautery.
Computed tomography image analysis
Digital axial CT scans performed preoperatively and used to
plan surgery were used to quantify skeletal muscle cross-
sectional area (CSA, cm2) as in our prior work.18,27 Measures
with CT have excellent precision (precision error values of
~1.5%).28 Briefly, images at the 3rd lumbar vertebra (L3) were
analysed for total L3-CSA within a specified Hounsfield unit
(HU) range (29 to +150) using Slice-O-Matic software
(v.4.3, Tomovision, Magog, Canada). Muscle area was normal-
ized for stature and reported as skeletal muscle index (SMI,
cm2/m2). Mean radiodensity (HU) was also reported. Adipose
tissue CSA at L3 was calculated in a HU range of 150 to 50
and 190 to 30, for visceral and subcutaneous adipose tis-
sue, respectively.28 The distribution of SMI of the patients
providing biopsy for this study was compared with a previ-
ously described large cohort of oncology patients (n = 1473)
to confirm that the population sampled is representative of
muscle mass distribution and mean values for our population
(Figure 2). Sarcopenia was classified according to previously
reported19,29 sex-specific and body mass index (BMI)-specific
criteria: for BMI <30 kg/m2, SMI <52.3 cm2/m2 for men and
<38.6 cm2/m2 for women, and for BMI ≥30 kg/m2, SMI
<54.3 cm2/m2 for men and <46.6 cm2/m2 for women.
Processing of muscle biopsy
From each biopsy, several analysis were performed, each
with specific preparation procedures. In the operating room,
visible adipose and connective tissue was removed from the
biopsy and it was cut into two pieces: one piece to be used
Figure 1 Flow chart of search. PRISMA diagram for the identification, screening, eligibility, and inclusion of papers (1 January 1990–16 August 2018)
from SCOPUS. All articles included investigated cancer, skeletal muscle, and muscle biopsies. Excluded records: review articles and ongoing clinical trials.
Characterization of muscle biopsies of cancer patients 3
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12466
for analysis of gene expression, and myosin heavy chain
(MyHC) by electrophoresis was immediately frozen in liquid
nitrogen in the operating room prior to being transported
to the lab for storage in liquid nitrogen until analysis. The
other piece of the biopsy to be used for microscopy was
transported on ice to the laboratory within 20 to 30 min.
For morphological preservation, isopentane (2-methylbutane,
C5H12) was cooled at 160°C in liquid nitrogen for 20 min or
until the appearance of a thick frozen layer at the bottom of
the container. A piece of muscle was oriented for transverse
section and delicately placed on aluminum foil. Tissue was
submerged in isopentane for 20 s, and aluminum foil was
turned upside down to allow full exposure of the muscle sec-
tion. After submersion, tissue was wrapped and left in liquid
nitrogen for 5 min. Information about surgery date, time, and
sample reception was documented.
Immunofluorescence: fibre types,
laminin/dystrophin, and nuclear stain
Muscle serial sections (10 μm) were cryosectioned (cryostat
Leica model CM300) transversely at 22°C and stored at
80°C until staining. MyHC I, IID, and IIA were determined
as previously described.30 Primary and secondary antibodies
are described in Supporting Information, Table S1. After the
secondary antibody application, a nuclear stain (4’,6-
diamidino-2-phenylindole) was added for 2 min and
washed. Slides (ApexTM superior adhesive slides, Leica
biosystems) were mounted, covered, and let dry for 12 h.
Images for tissue sections were acquired using a 20X/0.85
oil lens with a spinning disk confocal microscope (Quorum
Wave FX Spinning Disc Confocal System–Quorum technolo-
gies). Individual Z-stacked images were assembled to create
a composite image of a whole tissue cross section. Tissue
images were capture and analysed with Volocity 6.3 soft-
ware (PerkinElmer, Waltham, MA, USA). A software script
was established to identify muscle fibres types (I, I/IIA,
IIA, IIA/D, and D) using intensity of the MyHC stains and
quantified automatically by the software. Mean muscle fi-
bre area (μm2) was calculated by the detection of mem-
brane (laminin/dystrophin antibody) fluorescence of
muscle fibres in a cross section. Percentage of fibres with
centralized nuclei was manually assessed by selecting mus-
cle fibres with mispositioned nuclei (clearly separated from
sarcolemma, equidistant, or not) in a tissue cross section.
Figure 2 Figure represents overlap of L3 SMI distributions for male (A) and female (B) patients of current cancer population (small, light gray distri-
bution) and a cancer cohort with solid tumours of gastrointestinal tract and lung (big, dark gray distribution).1,2 (A) L3 SMI mean ± standard deviation
values are 50.8 ± 8.3 and 51.5 ± 8.9 cm2/m2 for the current population and Martin et al. gastrointestinal and lung cancer cohort, respectively. (B) L3
SMI mean values are 39.8 ± 6 and 41.3 ± 7 cm
2
/m
2
for the current population and Martin et al. gastrointestinal and lung cancer cohort, respectively. L3
SMI mean values for healthy 30-year-old kidney donor candidates (dotted line) are placed at 60.9 and 47.7 cm2/m2 for men and women, respectively.15
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Electrophoretic analysis of myosin heavy chain
isoform content
Semi-quantitative MyHC isoform analyses were completed on
frozen rectus abdominis using western blotting as previously
described.30–32 All three of the adult MyHC isoforms (I, IIA,
and IID) were clearly visible on all gels and reliably quantified
in at least triplicate by integrated densitometry (Syngene
ChemiGenius, GeneTools, Syngene).
Triglyceride content analysis
A piece of biopsy (50 mg) was ground using a frozen pestle
and mortar without letting the tissue thaw. Ground tissue
was homogenized in a 1.6 mL calcium chloride (CaCl2;
0.025%) solution with glass beads (0.5 mm diameter;
FastPrep ®-24, MP Biomedicals, Santa Ana, CA, USA) in 20
s intervals for 1 min. Samples were placed on ice for 15 s
between each homogenization interval. A modified Folch
method was used to extract lipids using chloroform/
methanol (2:1, vol/vol) as previously described.33,34 The
triglyceride (TG) fraction was isolated on G-plates and the
TG band was identified and scraped. An internal standard
C15:0 (10.2 mg/100 mL hexane) was added, followed by sa-
ponification and methylation. Samples were analysed using
gas liquid chromatography (flame ionization detector) on a
Varian 3900 (Varian Instruments, Georgetown, ON,
Canada). Quantity of fatty acids within the TG fraction
was calculated by comparison with the known concentra-
tion of the internal standard and sum of all fatty acids
was reported as total TG.
Gene expression: microarray
Microarray was conducted as previously described.23 The
data have been deposited in the U.S. National Center for Bio-
technology Information Gene Expression Omnibus25 and are
accessible through GEO series accession number GSE41726.
Statistical analysis
Statistical analyses were conducted in IBM® SPSS ® software,
version 24. A test for normal distribution was applied to the
continuous variables. Descriptive statistics were reported as
mean ± standard deviation. Comparisons between groups
were conducted using independent t-test or Mann–Whitney
U according to the variable normal distribution and χ2 test
for categorical variables. Statistical significance was consid-
ered at P values less than 0.05 (two-sided).
Results
Literature review
A total of 59 articles reporting analysis of skeletal muscle in
cancer populations were reviewed. The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses25 flow dia-
gram of our search strategy is shown in Figure 1.
Study quality and design
Table 1 includes all of the extracted data as well as scores for
sampling bias (Newcastle–Ottawa scale) and study quality
assessments (NIH). In general, the study quality rated as
low for the majority of studies (Table 1). Applying the
Newcastle–Ottawa criteria for sampling bias revealed the
majority of studies had a high risk of sampling bias with
58% of studies lacking representativeness, 96%
lacking sample size justification, and no study mentioned
non-respondent rate (% of population approached who de-
clined participation). Muscles biopsied were rectus abdominis
(n = 40), quadriceps (n = 20), tibialis anterior (n = 1), gastroc-
nemius (n = 1), pectoralis major (n = 1), sternocleidomastoid
(n = 1), serratus anterior (n = 1), diaphragm (n = 1), and
latissimus dorsi (n = 1), and in seven studies, more than one
muscle was collected. Four studies reported evaluation of
rectus abdominis from cancer patients and quadriceps for
non-cancer controls, and four studies reported biopsied mus-
cle from two or three different muscles.
Gastrointestinal cancers were the most common diagno-
ses; 31/59 studies included patients of exclusively one cancer
type: colorectal, pancreatic, gastric, breast, or prostate. Inclu-
sion of patients with two or more cancer types was reported
in 27/59 studies. Cancer stage or presence of metastasis was
described in 39/59 studies. Combined data from two or more
cancer stages were reported in 38/59 studies.
The majority of studies were cross sectional (Supporting
Information, Table S2). For investigation of patients with
cancer cachexia, weight loss was considered as the
main reference for classification. In 36 studies, weight loss
was graded with varying cut points (e.g. 5%, 10%, or
15%). Time frame of weight loss was not specified in 16
of these studies (Table 1). Percentage weight loss ranged
from 5% to 22% in weight-losing groups (Supporting
Information, Table S2). Measures of body composition
were included in 25 studies; however, these measures were
used to assess muscle mass or rate of muscle wasting
over time in only seven studies (Supporting Information,
Table S2).
Total sample size in each study was generally limited (mean,
n = 26; median n = 18; and range 1–134). Seventy-six per cent
of studies included n ≤ 30 cancer patients; 48/59 studies
included a non-cancer control group, sample size ranging from
n = 3 to 41. Fifty-two studies includedmen andwomen, 5 stud-
ies only men, 1 study only women, and 2 studies did not
Characterization of muscle biopsies of cancer patients 5
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specify the sex of their patients. For those studies including
both sexes, 50 had an imbalance between treatment groups
in the % of male and female patients, and only 3 studies
matched the number of male and female participants. When
reporting the results, almost all of the studies (98%) presented
aggregate data from men and women.
When a non-cancer control group was employed in the
study, the majority of studies included control groups that
went under surgical procedures (i.e. cholelithiasis and cho-
lecystitis, ovarian cyst, inguinal hernia, laparocele, abdomi-
nal aorta aneurysm, hemangioma of liver, gallstones, and
chronic pancreatitis) or healthy volunteers (Supporting In-
formation, Table S2). No study defined the criteria used
to select healthy volunteers. Table 1 highlights the features
of the cancer groups compared with control groups. More
than 54% of the studies included cancer patients with an
average age of ≥65 years, and for studies involving non-
cancer patients as controls, 26% included patients with an
average age of ≥65 years.
Most (33/59) reports failed to mention co-morbidities as a
component of their exclusion criteria or patient’s demograp-
hics. Commonly excluded diagnoses were diabetes, chronic
obstructive pulmonary disease, liver failure, renal failure,
chronic hepatitis, autoimmune diseases, and inflammatory
bowel disease. Use of medications (e.g. corticosteroids,
anabolic/catabolic agents, and/or beta blockers) was de-
scribed in 17 studies as clinical characteristics or exclusion
criteria. Prior exposure to antineoplastic drugs was reported
in 14/59 studies. Inclusion of patients naïve to chemotherapy
or radiotherapy was stated in 6/59 studies, two studies ac-
knowledged the inclusion of some patients with one or fewer
cycles of chemotherapy that concluded 4 weeks previous to
biopsy collection.
Technical considerations
Biobanking protocol and tissue manipulation
Abdominal and thoracic muscle biopsies were collected
during a surgical procedure in 43 studies, with collection
at the start of surgery being explicitly stated in 31 studies
(Table 2). Presence or absence of tissue cauterization was
specified in 29/43 studies. Percutaneous procedure (needle
biopsy) was the main method for collection of muscles of
the lower limb (n = 19 studies), open muscle biopsy
technique was reported in one study, and in one study, the
collection method was unspecified. For both surgical and per-
cutaneous biopsies, removal of blood traces and/or
fat/fibrotic tissue after collection was mentioned in 7/59
studies (Table 2).
Information provided on biopsy manipulation was limited
and mainly focused on freezing and storage procedures. In
43/59 studies, immediate freezing in liquid nitrogen was
reported. In only one study was it explicitly stated that
freezing was done in the operating room vs. a laboratory
facility. The most common temperatures for sample storage
were between 70°C and 80°C; storage details were not
mentioned in 11/59 studies. Details on time between biopsy
and transportation to laboratory facilities and waiting periods
were not reported in any study.
Rectus abdominis biological characterization
Study population
Demographics and clinical data from 190 patients are pro-
vided in Table 3. Nearly all patients (97%) who were
approached consented to intraoperative biopsy, as this
entails little, if any, incremental discomfort as the surgery
is inherently invasive. Therefore, there was no selection
bias inherent in the cohort. Typical of hepato-pancreatic-
biliary case load, 88% of cancers were gastrointestinal, with
the largest proportions being colorectal and pancreatic can-
cer. Surgical procedures included hepatectomy, liver
metastasectomy, pancreatectomy, Whipple procedure, bile
duct resection, cholecystectomy, colectomy, and gastrec-
tomy. Metastasis was present in 50% of the patients. Most
of the patients were naïve to chemotherapeutic agents,
23% had exposure to chemotherapy within 2 to 4 weeks
prior to the surgical procedure. The majority of patients
were classified as overweight. Diabetes type II and hyper-
tension were the most common co-morbidities. Most com-
monly used medications reported among the population
were analgesics, anti-inflammatory, statins, glucose-
lowering drugs, anti-hypertensives, anti-reflux, and thyroid
hormone replacement (Table 4).
Computed tomography image analysis
Muscle L3-CSA, SMI, and muscle radiodensity of rectus
abdominis and total muscle are shown in Table 5. Sarcopenia
was present in 56% of the patients, 60% (n = 97) of men and
49% (n = 42) of women. Weight history was available for 45
patients. Fifty-six per cent of patients experienced weight loss
(11 ± 12% in 5 ± 12 months), and 60% of weight-losing
patients were sarcopenic. Out of 44% (n = 20) weight stable
patients, 70% were sarcopenic.
Sex differences
In light of the fact that most of the papers in the literature
review included samples of mixed sex of varying propor-
tions, we examined all of the biopsy features for sex differ-
ences. Sexual dimorphism was prominent in L3-CSA total
lumbar muscle and RA, muscle radiodensity of RA and total
muscle (Table 5), mean fibre CSA (Table 6), and in expres-
sion of genes associated with muscle growth, apoptosis,
and inflammation (Table 7). Proportions of fibre types using
both quantification methods, MyHC isoforms and individual
fibre types, were not different between male and female
patients (Table 6).
For centralized nuclei assessment, the mean % of fibres
with centralized nuclei was 12 ± 9% (4 to 36%) and 10 ± 8%
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Table 2 Biopsy collection and handling procedures across the studies
Author
Biopsy collection (collected in
start or end of surgery) Cauterized
Blood traces, fat,
or connective
tissue removed
Sample handling and storage
conditions
Acharyya 200535 NR NR NR NR
Agustsson 201136 Initial phase of surgery NR NR Incubated in vitro
Aversa 201637 Initial phase of surgery No NR Immediately frozen, stored at 80°C
Aversa 201267 Initial phase of surgery No NR Immediately frozen, stored at 70°C
Banduseela 200786 Percutaneous biopsy (local
anaesthesia)
N/A Yes (fat,
connective
tissue)
Immediately frozen, stored at 80°C
Bohlen 201889 NR N/A NR Stored in RNA stabilization solution
at 4°C overnight and then stored
at 80°C
Bonetto 201338 Initial phase of surgery No NR Immediately frozen, stored at 80°C
Bossola 200639 Initial phase of surgery No NR Immediately frozen, stored at 70°C
Bossola 200140 Initial phase of surgery No NR Immediately frozen, stored at 70°C
Bossola 200341 Initial phase of surgery No NR Immediately frozen, stored at 70°C
Brzeszczynska 201671 Initial phase of surgery No Yes (blood) Immediately frozen, stored at 80°C
Busquets 200742 Initial phase of surgery No NR Immediately frozen, stored at 80°C
Christensen 201674 Percutaneous biopsy (local
anaesthesia)
N/A NR Immediately frozen, stored at 80°C
Christensen 201475 Percutaneous biopsy (local
anaesthesia)
N/A NR Immediately frozen, stored at 80°C
DeJong 200543 Initial phase of surgery No NR Immediately frozen, stored at 70°C
D’Orlando 201444 Initial phase of surgery No NR Immediately frozen, stored at 80°C
Ebhardt 201772 Percutaneous biopsy (local
anaesthesia)
N/A Yes (blood) Immediately frozen, stored at 80°C
Eley 200845 Initial phase of surgery No NR Immediately frozen, stored at 70°C
Gallagher 201273 Percutaneous biopsy (local
anaesthesia)
N/A Yes (blood) Immediately frozen, stored at 80°C
Higuchi 200087 NR N/A NR NR
Jagoe 200288 Initial phase of surgery No NR Immediately frozen, stored at 80°C
Johns 201722 Initial phase of surgery No NR Immediately frozen, stored in liquid nitrogen
Johns 201446 Initial phase of surgery NR Yes (blood) Immediately frozen, stored at 80°C
Khal 200547 NR No NR Immediately frozen, stored at 70°C
Lamboley 201776 Percutaneous biopsy (local
anaesthesia)
N/A Yes (blood) Immediately and stored in liquid nitrogen
Lundholm 197648 Initial phase of surgery NR NR Muscle fibre isolation on fresh tissue
MacDonald 201568 Initial phase of surgery and
percutaneous biopsy (local
anaesthesia)
NR NR Immediately frozen in liquid nitrogen,
storage temperature NR
Marzetti 201749 Initial phase of surgery No NR Immediately frozen, stored at 80°C
Narasimhan 201721 Initial phase of surgery No NR Immediately frozen, stored at 80°C
Narasimhan 201820 Initial phase of surgery No NR Immediately frozen, stored at 80°C
Nilsen 201677 Percutaneous biopsy (local
anaesthesia)
N/A Yes (fat) Frozen by immersion in isopentane, stored
at 80°C
Noguchi 199850 Initial phase of surgery NR NR Immediately frozen in situ, stored at 70°C
Op den Kamp 201578 Percutaneous biopsy (local
anaesthesia)
N/A NR Immediately frozen, stored at 70°C
Op den Kamp 201258 Percutaneous biopsy (local
anaesthesia)
N/A NR Immediately frozen, stored at 80°C
Op den Kamp 201380 Percutaneous biopsy (local
anaesthesia)
N/A NR Frozen by immersion in isopentane, stored
in 80°C
Pessina 201051 Initial phase of surgery No NR Immediately frozen, stored at 70°C
Phillips 201381 Percutaneous biopsy (local
anaesthesia)
N/A NR Immunoblotting in fresh tissue
Prokopchuk 201652 NR NR NR Immediately frozen and stored at 80°C
Puig-Vilanova 201482 Open muscle biopsy technique N/A NR NR
Ramage 201853 NR NR NR Immediately frozen, stored at 80°C
Rhoads 200954 Initial phase of surgery No NR Immediately frozen, stored at 70°C
Schmitt 200755 NR NR NR Immediately frozen in liquid nitrogen,
storage temperature NR
Shaw 199169 NR NR NR Snap-frozen in liquid nitrogen, thawed
after 48 h
Skorokhod 201256 Initial phase of surgery NR NR Immediately frozen in liquid nitrogen,
storage temperature NR
Smith 201157 Initial phase of surgery No NR Immediately frozen and stored at 80°C
(Continues)
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(3 to 27%) in men and women, respectively. No differences
were found between men and women (p=0.39) with a com-
bined mean value of 11 ± 8%.
Rectus abdominis: proportion of fibre types and muscle fibre
area
Electrophoretic analysis of MyHC isoforms confirmed MyHC
I and MyCH IIA to be present at similar proportions, while
MyHC IID was less abundant (Table 6A). MyHC type IIA was
the most abundant isotype, followed by MyHC type I and
IID (Table 6B). In addition, 15.5% of the fibres were identi-
fied as hybrids, which is the sum of MyHC type I/IIA and
IIA/D. For individual fibre types, type I fibres comprised
the greatest proportion (46.4%) followed by fibre type IIA
(36.1%) and hybrid type IIA/D (15%). Presence of fibre type
IID, as well as hybrid type I/IIA, was minimal (1.8% and
0.7%). Mean muscle fibre area (μm2) was calculated by
the detection of membrane (laminin/dystrophin antibody)
fluorescence on 1069 ± 771 muscle fibres per biopsy (Table
6C). Mean muscle fibre area was determined in total and
per fibre type, which includes collective results of MyHC
isoforms and individual fibre types (Table 6C). Mean fibre
area of MyHC type I was smaller than MyHC type IIA and
IID. For individual fibre types, type I and type I/IIA were
smaller compared with type IIA, IIA/D, and IID. Type IID
had the largest mean fibre area compared with the other
individual fibre types.
Age effects
Comparison of older (74 ± 4 years, n = 13) and younger (50 ± 6
years, n = 13) men revealed no differences between groups
with respect to mean muscle fibre area (total, individual fibre
types, or MyHC isoforms), % of individual fibre types, or % of
MyHC isoforms. Age effect was evaluated in men (n = 26) by
comparing mean values of a younger group vs. an older group.
No significant differences were found in relation to % of MyHC
isoform content.
Skeletal muscle gene expression for genes associated with
cancer cachexia
Differences in genes encoding proteins commonly explored in
cancer-muscle wasting are summarized in Table 7 (also see
Supporting Information, Table S3). Atrophy, autophagy, apo-
ptosis, muscle growth, and inflammation genes were selected
based on reviewed literature on muscle atrophy in can-
cer.22,40,41,47,50,70,87,88,108 Sexual dimorphism exists in path-
ways related to skeletal muscle anabolism and catabolism
illustrating the need for caution when generalizing results
from only one sex or discussing results from a mixed group
of cancer patients.
Table 2 (continued)
Author
Biopsy collection (collected in
start or end of surgery) Cauterized
Blood traces, fat,
or connective
tissue removed
Sample handling and storage
conditions
Stephens 201158 Initial phase of surgery NR NR Fixation for microscopy
Stephens 201070 Rectus abdominis–NR
Quadriceps–percutaneous
biopsy (local anaesthesia)
NR NR Immediately frozen
Stephens 201559 Initial phase of surgery NR Yes (blood) Immediately frozen, stored at 80°C
Stretch 201323 Initial phase of surgery No NR Immediately frozen and stored in liquid
nitrogen
Sun 201260 Initial phase of surgery NR NR Immediately frozen and stored at 80°C
Taskin 201461 NR NR NR Transferred to lab on ice cold buffer,
stored at 20°C
Weber 200783 Percutaneous biopsy (local
anaesthesia)
N/A NR Immediately frozen, stored at 80°C
Weber 200984 Percutaneous biopsy (local
anaesthesia)
N/A NR Immediately frozen, stored at 70°C
Williams 201285 Percutaneous biopsy (local
anaesthesia)
N/A NR NR
Williams 199962 Initial phase of surgery No NR Immediately frozen, stored at 70°C
Zampieri 201066 Rectus abdominis–NR
Quadriceps–Percutaneous biopsy
(local anaesthesia)
NR NR Immediately frozen and stored in liquid
nitrogen
Zampieri 200965 Rectus abdominis–NR
Quadriceps–Percutaneous biopsy
(local anaesthesia)
NR NR Immediately frozen and stored in liquid
nitrogen
Zampieri 201064 Rectus abdominis–NR
Quadriceps–Percutaneous biopsy
(local anaesthesia)
NR NR Immediately frozen and stored in liquid
nitrogen
Zeiderman 199163 Initial phase of surgery NR NR Incubation
N/A: not applicable.
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Discussion
There is a perceived need to understand the human biology
of cancer-associated muscle atrophy and to frame it in
the context of our larger understanding of experimental
findings.6,22,109–111 The emergent literature on human mus-
cle biopsies has been generated with that intent but has a
number of substantial limitations within the study design as
well as procedures for collection and preparation of the
biopsy material. At the same time, there is substantial op-
portunity for collaboration between cancer surgeons and
researchers to obtain intraoperative biopsies with a high
rate of patient consent and the additional capability to de-
scribe the muscles of these patients with precise radiologi-
cal metrics. Agreement to a set of standardized procedures
and reporting will enhance the consistency, reliability, and
comparability of future research in this area. Evaluation of
human rectus abdominis muscle presents the expected var-
iation in several measures that may be of interest for
emerging studies in this area.
Study quality and design
The quality of the studies reporting on biopsy material to
characterize varying features of muscle biology was uniformly
low. Quality assessment tools revealed several inconsis-
tencies in sample selection strategies, study design, data col-
lection, and analysis in the existing literature. Bias assessment
of sample selection exposed a clear absence of sample repre-
sentativeness in 59% of studies and lack of sample size justi-
fication in 96% of studies. In 75% of the studies reviewed,
samples from a relatively small number of participants (n =
Table 3 Patient characteristics
Male (n = 122) Female (n = 68) P values
Age, mean years ± SD (Min–Max) 61 ± 12 (19–87) 65 ± 12 (21–87) 0.049
Tumour type, % (n) 0.006
Colorectal 45 (55) 26 (18)
Pancreas 23 (28) 31 (21)
Other gastrointestinala 25 (31) 22 (15)
Otherb 6 (8) 20 (14)
Presence of metastasis, % (n) 56 (68) 40 (27) 0.03
Chemotherapy exposure within 4 weeks prior to muscle biopsy, % (n) 23 (28) 22 (15) 0.9
Patients with weight lost, % (n) 56 (14)c 55 (11)d 0.9
Sarcopenia, % (n) 60 (61)e 50 (23)f 0.2
BMI (kg/m2), mean ± SD 27 ± 5 28 ± 7 0.7
BMI classification, % (n) 0.1
Underweight 1 (1) 1 (1)
Normal 26 (32) 26 (18)
Overweight 39 (48) 28 (19)
Obesity I 17 (21) 6 (4)
Obesity II 5 (6) 10 (7)
Obesity III 2 (2) 4 (3)
Missing BMI 10 (12) 24 (16)
Co-morbidities, % (n)
Diabetes type II 12 (15) 18 (12) 0.3
Hypertension 24 (29) 29 (20) 0.4
Cardiovascular disease 15 (18) 7 (5) 0.1
Dyslipidemia 7 (9) 7 (5) 0.9
History of smoking habit, % (n) 28 (34) 24 (16) 0.3
Computed tomography, body composition analysis, mean ± SD
Subcutaneous adipose tissue (cm2) 166.4 ± 91.5g 251.1 ± 134.4h <0.001
Visceral adipose tissue (cm2) 174.8 ± 105.1g 111.9 ± 65.7h <0.001
Muscle biopsy triglyceride content (μg/mg), mean ± SD 13.2 ± 14.8i 29.5 ± 21.7j <0.001
Differences between men and women were analysed by independent t-test (continuous variables) and χ2 test (categorical variables). BMI,
body mass index.
aOther gastrointestinal: stomach, small intestine, liver, intrahepatic bile duct, gallbladder, biliary tract, and appendix.
bOther: adrenal gland, skin, kidney, mesothelium, lymphoma, melanoma, chronic lymphocytic leukemia, prostate, ovary, uterus, head,
and neck.
cPatients with weight loss information: n = 25.
dPatients with weight loss information: n = 20.
ePatients with sarcopenia information: n = 102.
fPatients with sarcopenia information: n = 46.
gCT adipose tissue information: n = 98.
hCT adipose tissue information: n = 44.
iPatients with muscle biopsy triglyceride content: n = 69.
jPatients with muscle biopsy triglyceride content: n = 19.
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≤30) were evaluated without accounting for age or sex
variation.
The majority of published studies use weight loss (vs.
weight stability) to define cachexia. This approach is limited
by not accounting for the characteristics of muscle (muscle
mass or change in muscle over time), which are the clinically
relevant features related to cancer outcomes. Indeed, weight
stable patients may well be losing muscle over time112 and
they can also be profoundly sarcopenic.2,27 Weight loss was
the most commonly used criteria for cancer cachexia assess-
ment; however, application of this measure alone poses ma-
jor concerns in misclassification and unintended exclusion of
cachectic patients. Many studies were published prior to
the widespread use of CT images to quantify muscle, as well
as prior to the publication of the international cachexia con-
sensus, which defines muscle mass as a diagnostic criterion
for cachexia.35,36,39–42,45,47,48,50,54,55,57,63–66,69,70,83,84,86–88,108
The premise of using weight loss when muscle is being
evaluated is erroneous. Muscle wasting can be experienced
by patients with less than 5% weight loss.112 Also, the arbi-
trary selection of weight loss percentage and time frame in
different studies complicates the comparison of results
between studies. In the cohort of patients we evaluated,
70% of weight stable patients and 60% of weight-losing
patients were sarcopenic. Therefore, assessment of muscle
mass is essential, and this can be easily achieved through
the secondary analysis of CT images used to plan the
surgery.18,19,29
Table 4 Most common medications prescribed and potential effects on skeletal muscle
Class of drug Medication
%
(n) Common use
Possible implications to
skeletal muscle
Cyclooxygenase inhibitors Aspirin and
acetaminophen
15 (29) Pain, fever, inflammation,
and prevention of
cardiovascular disease
Influence muscle
prostaglandin synthesis,
muscle protein metabolism,
and cellular processes
regulating muscle protein
synthesis90–93
HMG-CoA
reductase
inhibitors
Rosuvastatin,
simvastatin,
and atorvastatin
13 (24) Lipid lowering Association with myalgia
and related symptoms.
Associated to mitochondrial
oxidative stress94,95
Biguanide Metformin 8 (16) Type 2 diabetes, suppressor
of hepatic gluconeogenesis
Mitochondrial dysfunction
in skeletal muscle.
Sensitizes muscle to insulin;
increases glucose
disposal in skeletal
muscle95–98
Proton pump inhibitors Omeprazole
and
pantoprazole
8 (16) Gastroesophageal reflux
and erosive esophagitis
Concomitant administration
with atorvastatin and
dexamethasone is
associated to increase risk of
myopathy99
Hormones Levothyroxine 7 (13) Thyroid hormone (T4)
deficiency
Influences myogenesis,
associated with sarcopenia
and myopathy15,100
Angiotensin
converting
enzyme
inhibitor
Ramipril 7 (13) Hypertension and
congestive heart failure
Associated with larger
muscle cross sectional area
and muscle remodeling,
associated with cancer
cachexia99–104
Thiazide
diuretic
Hydrochloro-thiazide 6 (12) Hypertension and diuretic
by reducing sodium
reabsorption
None reported or reviewed
Calcium
channel
blockers
Amlodipine 5 (9) Hypertension and calcium
channel blocker
None reported and
reviewed105
Opioid Oxycodone 3 (5) Pain Hypogonadism and
testosterone depletion in
men106
Alpha-adrenergic blocker Tamsulosin 3 (5) Muscle relaxer of prostate
and bladder
None reported or reviewed
Xanthine oxidase inhibitor Allopurinol 3 (5) Gout prevention and
decrease blood uric acid
levels
Prevents skeletal muscle
atrophy107
Anticoagulant Warfarin 3 (5) Anticoagulant None reported or reviewed
Percentage of patients prescribed this medication out of a total of 190 patients who had a medical history available with information pro-
vided on current medication use.
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Table 5 Computed tomography defined muscle composition at L3 for rectus abdominis and total skeletal muscle in cancer patients, stratified by sex
and age decade
Sex
Age
stratum N
Rectus abdominis
Total lumbar
muscle
Lumbar skeletal
muscle index Rectus abdominis Total lumbar muscle
L3-CSA (cm2) cm2/m2 Radiodensity (Hounsfield units)
Male <50 17 15.9 ± 3.8
(9.8–23.4)
188.7 ± 29.1
(123.6–238.2)
58.2 ± 8.9
(42.8–73.3)
36.2 ± 12.3
(7.6–54.8)
39.6 ± 10.5
(15.4–55.3)
50–60 34 13.6 ± 3.9
(6.6–24.5)
156.2 ± 27.5
(107.2–228.9)
50.6 ± 8.2
(37.1–66.5)
30.9 ± 12.2
(4.4–50.0)
36.5 ± 8.9
(13.8–50.5)
60–70 23 13.3 ± 3.3
(5.7–19.4)
158.4 ± 20.7
(109.0–192.5)
50.8 ± 6.6
(36.4–60.8)
28.0 ± 12.3
(10.8–44.3)
33.8 ± 10.1
(7.1–54.4)
70–80 23 11.5 ± 2.6
(6.0–17.6)
141.4 ± 23.0
(94.6–187.2)
46.6 ± 6.0
(35.6–59.1)
20.0 ± 11.3
(2.0–44.6)
28.9 ± 7.7
(10.0–42.6)
>80 4 9.8 ± 4.2
(6.2–15.2)
139.0 ± 16.4
(122.8–160.9)
46.1 ± 7.1
(40.1–56.3)
21.5 ± 8.3
(12.3–30.4)
27.5 ± 3.0
(24.8–31.5)
Female <50 3 9.3 ± 3.2
(5.9–12.2)
114.9 ± 14.8
(97.8–124.4)
43.8 ± 1.6
(42.9–45.7)
32.0 ± 5.7
(26.6–38.0)
45.1 ± 5.3
(40.5–50.9)
50–60 11 7.0 ± 2.4
(3.8–10.9)
101.5 ± 16.8
(67.5–125.4)
38.3 ± 6.8
(23.9–46.4)
22.7 ± 13
(4.2–41.1)
35.4 ± 7.6
(20.9–46.1)
60–70 15 8.7 ± 3.7
(2.8–16.9)
102 ± 16.6
(66.2–122.7)
39.2 ± 7.0
(27.7–52.8)
19.1 ± 10.3
(2.5–39.1)
29.0 ± 7.1
(18.2–39.6)
70–80 16 6.7 ± 2.3
(1.4–10.9)
101.0 ± 13.8
(79.0–127.3)
40.5 ± 4.8
(33.8–49.7)
13.1 ± 10.0
(7.7–30.9)
28.9 ± 7.0
(15.0–38.9)
>80 3 7.7 ± 3.1
(4.2–10.0)
92.8 ± 14.8
(77.9–107.5)
41.1 ± 8.1
(32.9–49.1)
12.2 ± 19.8
(10.1–27.6)
22.9 ± 4.1
(18.225.3)
Total male 101 13.6 ± 3.8
(5.7–24.5)
158.2 ± 29 (94.6–238.2) 50.8 ± 8.3
(35.6–73.3)
28.2 ± 12.9
(10.8–54.8)
34.3 ± 9.7
(7.1–55.3)
Total female 48 7.6 ± 2.9
(1.4–16.9)
101.7 ± 15.4
(66.2–127.3)
39.8 ± 6
(23.9–52.8)
18.2 ± 12
(10.1–41.1)
31 ± 8.3
(15–50.9)
Values reported in mean ± SD (range). CSA, cross-seccional area; L3, 3rd Lumbar vertebra.
Table 6 Rectus abdominis myosin heavy chain content and mean muscle fibre area of cancer patients
All Male Female P value
A. MyHc content by electrophoresisa (% ± SD N = 40 M/n = 8 F)
MyHC I (%) 39.3 ± 11.1 39.1 ± 10.3 40.6 ± 15.6 0.73
MyHC IIA (%) 38.4 ± 11.1 37.5 ± 10.0 42.6 ± 15.7 0.24
MyHC IID (%) 22.3 ± 8.9 23.4 ± 8.6 16.8 ± 9.1 0.06
B. MyHc content by immunohistochemistrya (% ± SD N = 20 M/n = 10 F)
MyHC isoforms (%)
MyHC type I 47.1 ± 13.0 47.0 ± 12.6 47.3 ± 14.6 0.91
MyHC type IIA 51.8 ± 13.4 52.4 ± 12.6 50.5 ± 15.6 0.53
MyHC type IID 16.7 ± 14.3 19.2 ± 13.7 11.8 ± 15.1 0.19
All Hybridsb 15.5 ± 13.5 18.5 ± 13.5 9.6 ± 12.2 0.08
Individual fibre types (%)
Fibre type I 46.4 ± 12.9 48.9 ± 9.4 46.2 ± 14.2 0.32
Fibre type I/IIA 0.7 ± 1.0 0.6 ± 0.9 1.2 ± 1.6 0.15
Fibre type IIA 36.1 ± 9.5 35.7 ± 9.4 40.7 ± 9.6 0.71
Fibre type IIA/D 15.0 ± 13.7 13.1 ± 12.4 8.5 ± 12.9 0.39
Fibre type IID 1.8 ± 4.6 1.7 ± 3.7 3.4 ± 7.3 0.32
C. Mean muscle fibre area (μm2) (% ± SD N = 20 M/n = 10 F)
All fibres 3236 ± 1390 3784 ± 1285 2139 ± 854 <0.05
MyHC isoforms (μm2)
MyHC type I 2323 ± 944 2591 ± 970 1786 ± 635 <0.05
MyHC type IIA 4009 ± 1937 4848 ± 1725 2331 ± 1054 <0.05
MyHC type IID 4026 ± 2060 4722 ± 1895 2461 ± 1546 <0.05
Individual fibre types (μm2)
Fibre type I 2325 ± 941 2591 ± 970 1795 ± 633 <0.05
Fibre type I/IIA 2253 ± 1209 2726.6 ± 1181 1306 ± 528 <0.05
Fibre type IIA 3940 ± 1970 4760 ± 1820 2299 ± 1012 <0.05
Fibre type IIA/D 4012 ± 2055 4833.5 ± 1841 2266 ± 1268 <0.05
Fibre type IID 5243 ± 2407 5323 ± 2553 4729 ± 1524 0.75
MyHC: myosin heavy chain.
aThere were no differences in age, BMI, metastasis, chemotherapy exposure, co-morbidities, nor smoking history between men and
women.
bAll hybrids refer to fibres of mixed myosin heavy chain isoforms MyHC type I/IIA and MyHC type I.
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Some authors reported mortality-defined cutpoints to de-
fine sarcopenia according to age and sex of a reference pop-
ulation27,113 and these have been secondarily used by other
authors.114 Caution should be used in applying these
cutpoints to define sarcopenia in patients undergoing muscle
biopsy, and these may not necessarily reflect the population
from which biopsies are evaluated.114 Here, we suggest to
use CT to quantify muscle features for the overall population
from which the biopsy sampling is done. In this way, patients
providing biopsy for our study are clearly representative of
the entire L3 SMI distribution of our regional population
(Alberta, Canada) (Figure 2). This representation eliminates
the possibility of sampling bias. It also allows each patients’
SMI to be ranked within the population distribution overall
as well as compared with values available for healthy young
individuals.115
Age and sex differences exist at the level of muscle func-
tion, biochemistry/metabolism, and mass.14,17,116 The major-
ity of studies reported combined data from both sexes
without acknowledging sexual dimorphisms. Age was gener-
ally not accounted for. In the first 40 years of life, muscle
mass is relatively stable in both men and women, and then
it begins to decline; however, the rate of loss is slower in
women than in men.62 In our sample, differences between
men and women were observed for muscle fibre area, SMI,
and muscle radiodensity. Sexual dimorphism in gene expres-
sion was not limited to a particular pathway or function but
was identified in growth (AKT1, FOXO1, MSTN, PAX7, and
TGFα1), apoptosis (CASP9), and inflammation (TNF and
STAT3). In relation to the age effect, we did not find any sig-
nificant differences in mean muscle fibre area and proportion
of fibre types when comparing young vs. old male cancer pa-
tients; this could be potentially explained by the narrow age
range in our study. Differences between young (18 to 48
years) and older (66 to 99 years) participants117 have been re-
ported for fibre type distribution in rectus abdominis and
vastus lateralis. Therefore, age differences and sexual dimor-
phism must be acknowledged when comparing, reporting,
and interpreting muscle characteristics.
Here, we present many characteristics of human rectus
abdominis muscle. We obtained a detailed analysis of its ra-
diological features, for the first time. Our analysis of fibre
Table 7 Skeletal muscle gene expression for genes associated with cancer cachexia in cancer patientsa
Biological function Gene symbol Gene name Agilent transcript ID [Refseq RNA ID]
Female
(n = 64)
Male
(n = 69) P value
Atrophy FOXO1 Forkhead box O1 A_24_P22079 1.53 ± 1.04 1.11 ± 0.68 0.005
Autophagy BECN1 Beclin 1 A_23_P433071 [NM_003766] 0.91 ± 0.27 1.03 ± 0.3 0.05
A_23_P89410 [NM_003766] 1.00 ± 0.27 1.11 ± 0.33 0.05
CTSL2 Cathepsin L2 A_23_P146456 [NM_001333] 1.31 ± 0.57 0.99 ± 0.44 <0.0001
Apoptosis CASP8 Caspase 8 A_23_P209389 [NM_033355] 0.97 ± 0.32 1.09 ± 0.38 0.08
CASP9 Caspase 9 A_23_P97309 [NM_001229] 0.95 ± 0.19 1.06 ± 0.25 0.008
A_24_P111342 [NM_001229] 0.97 ± 0.22 1.08 ± 0.31 0.03
Muscle growth AKT1 V-Akt murine
thymoma
viral oncogene
homolog 1
A_23_P2960 [NM_005163] 1.23 ± 0.52 1.04 ± 0.35 0.03
DMD Dystrophin A_24_P342388 [NM_004019] 1.34 ± 0.67 0.94 ± 0.29 <0.0001
A_24_P185854 [NM_004010] 1.11 ± 0.27 0.94 ± 0.23 <0.0001
A_24_P34186 [NM_004010] 1.19 ± 0.55 0.97 ± 0.39 0.01
A_32_P199796 [NM_004023] 1.27 ± 0.66 0.98 ± 0.42 0.005
MSTN Myostatin A_23_P165727 [NM_005259] 1.71 ± 2.43 2.74 ± 3.74 0.02
PAX7 Paired box 7 A_23_P126225 [NM_013945] 0.99 ± 0.49 1.08 ± 0.39 0.05
A_23_P500985 [NM_013945] 0.96 ± 0.45 1.03 ± 0.33 0.09
PPARGC1A Peroxisome proliferator-
activated receptor gamma,
coactivator 1 alpha
A_24_P303052 [NM_013261] 1.22 ± 0.77 1.00 ± 0.51 0.07
SMAD3 SMAD family member 3 A_23_P48936 [NM_005902] 1.14 ± 0.42 1.00 ± 0.28 0.07
TGFB1 Transforming growth
factor, beta 1
A_24_P79054 [NM_000660] 1.42 ± 1.47 1.06 ± 0.54 0.01
Inflammation JAK1 Janus kinase 1 A_24_P410678 [NM_002227] 0.92 ± 0.37 1.15 ± 0.43 0.001
JAK2 Janus kinase 2 A_23_P123608 [NM_004972] 1.21 ± 0.48 1.06 ± 0.45 0.03
JAK3 Janus kinase 3 A_23_P329112 [NM_000215] 1.03 ± 0.46 1.19 ± 0.57 0.09
STAT3 Signal transducer
and activator of
transcription 3
A_23_P107206[NM_213662] 1.21 ± 1.02 0.53 ± 0.35 0.02
STAT5A Signal transducer
and activator of
transcription 5A
A_23_P207367 [NM_003152] 1.12 ± 1.01 0.32 ± 0.34 0.03
A_24_P173088 [NM_003152] 1.19 ± 1.00 0.47 ± 0.45 0.005
TNF Tumor necrosis factor A_24_P50759 [NM_000594] 0.99 ± 0.35 1.15 ± 0.44 0.03
Values (unitless) reported as mean ± standard deviation.
aCancer type (0.003) and metastasis presence (0.002) were different between men and women. There were no differences in age, BMI,
chemotherapy exposure, co-morbidities, nor smoking history between men and women.
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type is multidimensional and confirms the mixed fibre dis-
tribution of the rectus abdominis. A prior study in cancer
patients with upper gastrointestinal malignancies reported
mean values of 48% and 55% for MyHC type I and IIa, re-
spectively46. Muscle gene expression and TG content levels
as presented here are new information about rectus
abdominis. Future work on rectus abdominis can be use-
fully planned, using this base of information. The majority
of evidence to date (Table 1) on muscle from cancer pa-
tients is coming from rectus abdominis. Due to the unique
characteristics of each muscle type, we suggest that future
researchers identify candidate muscles for intensive re-
search using the principle that the muscle(s) most often
transected in cancer surgeries would be the greatest re-
source. This can be decided in function of the common sur-
gical approaches. Thus, over time, a large base of evidence
may be obtained from latissimus dorsi, serratus anterior, or
intercostal muscle (e.g.) from thoracic cancer surgeries.
A key component of case-control studies is to provide de-
tails of the control group relative to the research question.
However, this is rarely done in the literature that we
reviewed.20,21 Detailed clinical characterization of non-cancer
controls is usually missing, and assumption of a healthier sta-
tus of the control group when compared with cancer patients
is common. In many cases, the comparator group is a non-
cancer surgical patient population; however, there is no doc-
umentation provided around diagnosis or medications. Pre-
sumably, healthy volunteers could have underlying co-
morbid conditions or be taking medications that impact skel-
etal muscle. Co-morbidities and use of medications were not
generally mentioned either for patients undergoing non-
cancer surgery or ‘healthy’ volunteers recruited outside the
clinical setting. Approximately 60% of people diagnosed with
malignancy are 65 years and older.13 Prevalence of co-
morbidity in cancer population ranges from 30% to 50% de-
pending on type of cancer19 and a patient with history of can-
cer has on average three co-morbidities.118,119 Diabetes and
hypertension were the most common conditions in our pa-
tient population, but cardiovascular disorders and mental
health problems are also prevalent in the cancer popula-
tion.13,19 These chronic conditions and medications taken to
control them can independently affect muscle physiol-
ogy15,106,120–128 (Table 4). COX inhibitors, statins, biguanides,
proton pump inhibitors, and thyroid hormones were the
most common medications prescribed in our patient popula-
tion apart from those prescribed during cancer treatment.
These classes of drugs have known effects on muscle protein
synthesis90–92,129 and catabolism,130–133 atrophy path-
ways,134 insulin sensitivity,96 and mitochondria function.97
Therefore, it is important that for both the cancer group
and ‘control’ groups have a detailed medical history that cap-
tures diagnosis of other conditions and medications. In addi-
tion to drugs prescribed for management of co-morbid
conditions, antineoplastic treatment previous to tissue biopsy
is also a relevant event that may impact interpretation of
results as the long-lasting effects in the muscle are
unknown.135
Technical considerations
We suggest recommendations for minimum procedures to
follow in biobanking practices, tissue manipulation, and pa-
tient characterization to enhance the consistency, reliability,
and comparability of future research (Table 8). Acknowl-
edgement of differences between muscle groups is essen-
tial when comparing and interpreting results. RA is
commonly collected in patients with gastrointestinal disease
due to its practicality in relation to the surgical incision
while maintaining patient burden to the essential minimum.
Its broad extension in the abdominal area enables for col-
lection of muscle tissue from a variety of locations136; how-
ever, no one has demonstrated how homogeneous the RA
is in relation to the biopsy site. On the other hand,
Table 8 Summary of recommendations for muscle biopsy processing and
population characterization
(A) Biobanking protocols and tissue manipulation
· For intraoperative muscle biopsies, collect at the start of the
surgical procedure and avoid cauterization.
· Avoid or report the use of foreign substances (e.g. use of
saline-moistened gauzes).
· Report waiting periods between surgical/needle removal,
transportation to other facilities, and freezing; include the use
or not of crushed ice during the waiting process.
· Report any removal of blood traces or unrelated tissue from
the muscle biopsy.
· If muscle is ‘immediately frozen,’ clarify the location, time, and
other relevant details (e.g. RNA stabilizer solution) of this action
after the surgical removal.
· Sample storage recommended ≤70°C; however, the
temperature selection will depend on the molecules of interest
and/or experimental techniques.
(B) Cancer population characterization
· Clearly state the patient selection method and possible
limitations.
· Report information on metastatic status or tumour
classification.
· Report co-morbidities and medications.
· Report past or current exposure of antineoplastic treatments.
(C) Inclusion of control groups
· Provide a clear characterization of the control group.
· Report co-morbidities and medications.
· Match age and sex with study population. Provide justification
for case-matching criteria.
· Collect same muscle in control and study populations.
(D) Classification and results
· Avoid mixing the results of two or more muscle groups or
comparing one muscle group with a different muscle group
(e.g. rectus abdominis vs. quadriceps).
· Acknowledge sexual dimorphism in skeletal muscle by
reporting results based in men and women, include mean and
standard deviation.
· Classification of cancer cachexia should include both, body
composition analysis (muscle mass values) and weight loss.
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quadriceps or tibialis anterior are collected in healthy vol-
unteers serving as controls as there is no justification for
surgical intervention. Importantly, physiological variations
between muscle groups exist,137,138 which strongly suggest
that studies collecting different muscles must avoid com-
paring or combining data of more than one muscle.
Most researchers did not report on surgical procedures and
muscle biopsy collection, transport, and processing of the
samples, each of which can impact on the morphological and
molecular profile of the biopsy.10,139,140 Collecting abdominal
muscle biopsies at the start of the surgical procedure and
avoidance of electrocautery is strongly recommended to re-
duce variations associated with the surgical trauma, variable
duration of surgery, and intraoperative effect of anaes-
thetics.10,11,141–144 Skeletal muscle collected at the start and
end of a surgery expresses differences in genes associated
with inflammation, growth differentiation, and transcription
factors.142 For percutaneous biopsies, the Bergstrom protocol
is a well-developed method with several adjustments to im-
prove the quality of the muscle biopsies.145,146 Procedures
followed after biopsy collection must also be detailed as sam-
ple preservation and storage impacts on muscle integrity and
potentially interpretation of the results. Lastly, the numbers
of medical conditions and drugs taken by patients in this sam-
ple are important and all of these and their different combina-
tions may have an impact on specific aspects of muscle
biology. As much as possible, we recommend to annotate
the presence of co-morbidities and medications in patients
consenting to biopsy.
Overall, the literature review reveals a high risk of sampling
bias and poorly characterized patient populations. These fea-
tures make reliable comparison between studies and aggrega-
tion of data challenging. Muscle biopsy preparation and
biobanking practices are also variable between studies. Data
from an unbiased sample of 190 patients present a variety of
measures of interest on rectus abdominis to provide a point
of reference for researchers exploring biological characteris-
tics of this muscle. Continued collaboration between re-
searchers and cancer surgeons would enable a more
complete understanding of mechanisms of cancer-associated
muscle atrophy.
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